A Prospective, Multicentre, Epidemiological Study Assessing the Impact of Childhood Vaccination with PCV13 and PCV7 on Distribution of Streptococcus Pneumonia Serotypes (PCV13 and PCV7) in Immunocompetent Adults Hospitalized with Community Acquired Pneumonia (CAP)

Trial Profile

A Prospective, Multicentre, Epidemiological Study Assessing the Impact of Childhood Vaccination with PCV13 and PCV7 on Distribution of Streptococcus Pneumonia Serotypes (PCV13 and PCV7) in Immunocompetent Adults Hospitalized with Community Acquired Pneumonia (CAP)

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal 7-valent CRM197 vaccine conjugate
  • Indications Community-acquired pneumonia
  • Focus Therapeutic Use
  • Acronyms CAPA
  • Sponsors Pfizer
  • Most Recent Events

    • 17 Aug 2017 Results published in the Vaccine Journal.
    • 12 May 2017 New trial record
    • 25 Apr 2017 Results presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top